# Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta

> **NCT02650973** · PHASE1 · COMPLETED · sponsor: **Coherus Oncology, Inc.** · enrollment: 122 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CHS-1701
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT02650973
- **Lead sponsor:** Coherus Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2016-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02650973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02650973, "Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02650973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*